s fradiae (DSMZ)
Structured Review

S Fradiae, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s fradiae/product/DSMZ
Average 93 stars, based on 8 article reviews
Images
1) Product Images from "Extensive natural variation in bacterial ribosomal drug-binding sites."
Article Title: Extensive natural variation in bacterial ribosomal drug-binding sites.
Journal: Cell reports
doi: 10.1016/j.celrep.2025.115878
Figure Legend Snippet: Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. fradiae (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).
Techniques Used: Binding Assay, Sequencing, Comparison, Concentration Assay
Figure Legend Snippet: Figure 6. rRNA substitutions that cause drug resistance in model organisms are widespread among natural bacterial species (A) rRNA secondary structure diagrams illustrate divergence in the evernimicin-binding pocket between S. fradiae and E. coli ribosomes. (B) Cryo-EM map of S. fradiae shows the divergent drug-binding site. (C) Comparison of experimental and AlphaFold3-predicted structures of S. fradiae’s evernimicin-binding pocket reveals nearly identical conformations (all-atom RMSD = ∼0.3 A˚ ), validating AlphaFold’s utility for assessing rRNA substitution effects. (D) Superposition of vacant S. fradiae ribosome with evernimicin-bound E. coli structure. (E–P) Comparisons of wild-type E. coli binding sites with AlphaFold3-predicted divergent sites across species demonstrate how rRNA variation alters pocket conformation, with each box summarizing the reported drug affinity impacts of substitutions and phylogenetic distribution of variants. Asterisks indicate sequence variants that have a variable impact on drug affinity that depends on the surrounding context in rRNA. (E)–(J) correspond to the large subunit and (K)–(P) to the small subunit. Overall, (E)–(P) show that changes at the direct ribosome-drug interface—even in the absence of apparent steric clashes or disrupted hydrophobic stacking interactions—typically lead to resistance.
Techniques Used: Binding Assay, Cryo-EM Sample Prep, Comparison, Sequencing